201 related articles for article (PubMed ID: 29802984)
1. Development of rectal enema as microbicide (DREAM): Preclinical progressive selection of a tenofovir prodrug enema.
Hoang T; Date AA; Ortiz JO; Young TW; Bensouda S; Xiao P; Marzinke M; Rohan L; Fuchs EJ; Hendrix C; Gumber S; Villinger F; Cone RA; Hanes J; Ensign LM
Eur J Pharm Biopharm; 2019 May; 138():23-29. PubMed ID: 29802984
[TBL] [Abstract][Full Text] [Related]
2. Hypo-osmolar Formulation of Tenofovir (TFV) Enema Promotes Uptake and Metabolism of TFV in Tissues, Leading to Prevention of SHIV/SIV Infection.
Xiao P; Gumber S; Marzinke MA; Date AA; Hoang T; Hanes J; Ensign LM; Wang L; Rohan L; Fuchs EJ; Hendrix C; Villinger F
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084755
[TBL] [Abstract][Full Text] [Related]
3. Tenofovir Douche as HIV Preexposure Prophylaxis for Receptive Anal Intercourse: Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics (DREAM 01).
Weld ED; McGowan I; Anton P; Fuchs EJ; Ho K; Carballo-Dieguez A; Rohan LC; Giguere R; Brand R; Edick S; Bakshi RP; Parsons T; Manohar M; Seigel A; Engstrom J; Elliott J; Jacobson C; Bagia C; Wang L; Al-Khouja A; Hartman DJ; Bumpus NN; Spiegel HML; Marzinke MA; Hendrix CW
J Infect Dis; 2024 Apr; 229(4):1131-1140. PubMed ID: 38019657
[TBL] [Abstract][Full Text] [Related]
4. RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate.
Anton PA; Cranston RD; Kashuba A; Hendrix CW; Bumpus NN; Richardson-Harman N; Elliott J; Janocko L; Khanukhova E; Dennis R; Cumberland WG; Ju C; Carballo-Diéguez A; Mauck C; McGowan I
AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1412-21. PubMed ID: 22943559
[TBL] [Abstract][Full Text] [Related]
5. MALDI Mass Spectrometry Imaging Reveals Heterogeneous Distribution of Tenofovir and Tenofovir Diphosphate in Colorectal Tissue of Subjects Receiving a Tenofovir-Containing Enema.
Seneviratne HK; Hendrix CW; Fuchs EJ; Bumpus NN
J Pharmacol Exp Ther; 2018 Oct; 367(1):40-48. PubMed ID: 30037813
[TBL] [Abstract][Full Text] [Related]
6. An Open-Label Pharmacokinetic and Pharmacodynamic Assessment of Tenofovir Gel and Oral Emtricitabine/Tenofovir Disoproxil Fumarate.
McGowan IM; Kunjara Na Ayudhya RP; Brand RM; Marzinke MA; Hendrix CW; Johnson S; Piper J; Holtz TH; Curlin ME; Chitwarakorn A; Raengsakulrach B; Doncel G; Schwartz JL; Rooney JF; Cranston RD
AIDS Res Hum Retroviruses; 2022 Apr; 38(4):279-287. PubMed ID: 34541872
[TBL] [Abstract][Full Text] [Related]
7. Validation and implementation of liquid chromatographic-mass spectrometric (LC-MS) methods for the quantification of tenofovir prodrugs.
Hummert P; Parsons TL; Ensign LM; Hoang T; Marzinke MA
J Pharm Biomed Anal; 2018 Apr; 152():248-256. PubMed ID: 29433097
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous determination of tenofovir alafenamide and its active metabolites tenofovir and tenofovir diphosphate in HBV-infected hepatocyte with a sensitive LC-MS/MS method.
Ouyang B; Zhou F; Zhen L; Peng Y; Sun J; Chen Q; Jin X; Wang G; Zhang J
J Pharm Biomed Anal; 2017 Nov; 146():147-153. PubMed ID: 28881311
[TBL] [Abstract][Full Text] [Related]
9. High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women.
Carballo-Diéguez A; Balán IC; Brown W; Giguere R; Dolezal C; Leu CS; Marzinke MA; Hendrix CW; Piper JM; Richardson BA; Grossman C; Johnson S; Gomez K; Horn S; Kunjara Na Ayudhya RP; Patterson K; Jacobson C; Bekker LG; Chariyalertsak S; Chitwarakorn A; Gonzales P; Holtz TH; Liu A; Mayer KH; Zorrilla C; Lama J; McGowan I; Cranston RD
PLoS One; 2017; 12(7):e0181607. PubMed ID: 28750059
[TBL] [Abstract][Full Text] [Related]
10. In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate.
Callebaut C; Stepan G; Tian Y; Miller MD
Antimicrob Agents Chemother; 2015 Oct; 59(10):5909-16. PubMed ID: 26149992
[TBL] [Abstract][Full Text] [Related]
11. Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog-Associated Mutations and M184V.
Margot N; Ram R; Abram M; Haubrich R; Callebaut C
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31988104
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection.
Duwal S; Schütte C; von Kleist M
PLoS One; 2012; 7(7):e40382. PubMed ID: 22808148
[TBL] [Abstract][Full Text] [Related]
13. Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus.
Ray AS; Fordyce MW; Hitchcock MJ
Antiviral Res; 2016 Jan; 125():63-70. PubMed ID: 26640223
[TBL] [Abstract][Full Text] [Related]
14. Hypo-osmolar rectal douche tenofovir formulation prevents simian/human immunodeficiency virus acquisition in macaques.
Xiao P; Gumber S; Marzinke MA; Hoang T; Myers R; Date AA; Hanes J; Ensign LM; Wang L; Rohan LC; Cone R; Fuchs EJ; Hendrix CW; Villinger F
JCI Insight; 2022 Dec; 7(23):. PubMed ID: 36477356
[TBL] [Abstract][Full Text] [Related]
15. Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors.
García-Lerma JG; Aung W; Cong ME; Zheng Q; Youngpairoj AS; Mitchell J; Holder A; Martin A; Kuklenyik S; Luo W; Lin CY; Hanson DL; Kersh E; Pau CP; Ray AS; Rooney JF; Lee WA; Heneine W
J Virol; 2011 Jul; 85(13):6610-7. PubMed ID: 21525346
[TBL] [Abstract][Full Text] [Related]
16. Establishment of intracellular tenofovir-diphosphate as the key determinant for in vitro-in vivo translation of antiviral efficacy.
Ma B; Barth A; McHale CM; Lai MT
Antiviral Res; 2018 Mar; 151():1-3. PubMed ID: 29337165
[TBL] [Abstract][Full Text] [Related]
17. Estimated pill intake with on-demand PrEP with oral TDF/FTC using TFV-DP concentration in dried blood spots in the ANRS IPERGAY trial.
Goldwirt L; Bauer R; Liegeon G; Charreau I; Delaugerre C; Cotte L; Pialou G; Cua E; Laghzal A; Buschman L; Anderson PL; Mourah S; Meyer L; Molina JM;
J Antimicrob Chemother; 2021 Sep; 76(10):2675-2680. PubMed ID: 34278433
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and efficacy of topical inserts containing tenofovir alafenamide fumarate and elvitegravir administered rectally in macaques.
Makarova N; Singletary T; Peet MM; Mitchell J; Holder A; Dinh C; Agrahari V; Mendoza M; Pan Y; Heneine W; Clark MR; García-Lerma JG; Smith JM; Doncel GF
EBioMedicine; 2022 Dec; 86():104338. PubMed ID: 36343572
[TBL] [Abstract][Full Text] [Related]
19. MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel.
Cranston RD; Lama JR; Richardson BA; Carballo-Diéguez A; Kunjara Na Ayudhya RP; Liu K; Patterson KB; Leu CS; Galaska B; Jacobson CE; Parikh UM; Marzinke MA; Hendrix CW; Johnson S; Piper JM; Grossman C; Ho KS; Lucas J; Pickett J; Bekker LG; Chariyalertsak S; Chitwarakorn A; Gonzales P; Holtz TH; Liu AY; Mayer KH; Zorrilla C; Schwartz JL; Rooney J; McGowan I;
Clin Infect Dis; 2017 Mar; 64(5):614-620. PubMed ID: 27986684
[TBL] [Abstract][Full Text] [Related]
20. Tenofovir alafenamide (TAF) does not deplete mitochondrial DNA in human T-cell lines at intracellular concentrations exceeding clinically relevant drug exposures.
Stray KM; Park Y; Babusis D; Callebaut C; Cihlar T; Ray AS; Perron M
Antiviral Res; 2017 Apr; 140():116-120. PubMed ID: 28131805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
